Sermorelin

evidence score
gh secretagogue
Prescription Only
GHRH 1-29GRF 1-29Geref+1 more

Sermorelin is a synthetic analog of the first 29 amino acids of growth hormone releasing hormone (GHRH 1-29). Unlike HGH, it stimulates the pituitary to produce GH in a pulsatile, physiological manner rather than delivering exogenous GH. FDA-approved for pediatric GH deficiency diagnosis and treatment; widely prescribed off-label by anti-aging and longevity physicians. Advantages over exogenous HGH: preserves pituitary function, more physiological GH pulses, lower feedback suppression, significantly lower cost. Often combined with GHRP-2 or ipamorelin to maximize GH pulse amplitude via dual-axis stimulation.

Evidence

No score yet

Safety

Unknown safety profile

Clinical Status

No formal phase listed

Research Sync

Not synced yet

Dosing

Typical
300 mcg
100 mcgRange500 mcg
Frequencydaily (bedtime)

Set height & weight in Settings to see your dose.

Pharmacology

Half-life~11-12 minutes (plasma)
OnsetGH elevation within 15-30 minutes of injection; body composition changes 3-6 months
DurationSingle dose GH pulse 1-2 hours; cumulative effects require months
Routes
subcutaneous_injection

Evidence Score

0 studies indexed
Scoring Factors
Volume(40%)
Quality(30%)
Sample Size(10%)
Consistency(10%)
Replication(5%)
Recency(5%)
Evidence Levels
AScore ≥75 with at least 1 meta-analysis and 3+ RCTs
BScore ≥50 with at least 1 RCT or meta-analysis
CScore ≥25 — observational or animal evidence only
DScore <25 — very limited or preclinical data

Plain-English Snapshot

Sermorelin is currently categorized as a gh secretagogue compound.

Evidence scoring has not been fully computed yet, so interpret this profile as preliminary.

Safety scoring is incomplete. Start conservatively and monitor carefully.

Core mechanism

GHRH receptor agonist in anterior pituitary somatotrophs; increases cAMP via Gs-coupled receptor; amplifies pulsatile GH release; preserves hypothalamic-pituitary axis

Practical Context

Strongest current signals

No indexed study summaries yet.

Compound Profile